摘要
【摘要】 目的 观察浓钠联合托伐普坦对慢性心力衰竭（心衰）并低钠血症的治疗效果， 并分析其对患者预后及生存质量的影响。方法 80例慢性心衰并低钠血症患者， 根据治疗方法不同分为对照组和研究组， 每组 40例。对照组患者采用常规治疗， 研究组患者采用常规治疗 +浓钠 +托伐普坦治疗。对比两组患者治疗效果、死亡率以及治疗前后生存质量评分。结果 研究组患者临床总有效率 95.00%高于对照组的 70.00%， 死亡率 0低于对照组的 10.00%， 差异均有统计学意义（ P<0.05）。治疗前， 两组患者明尼苏达心功能不全生命质量量表（ MLHFQ）评分比较差异无统计学意义（ P>0.05） ;治疗后， 两组患者 MLHFQ评分均低于本组治疗前， 且研究组 MLHFQ评分（ 30.13±2.09）分低于对照组的（ 44.98±5.56）分， 差异具有统计学意义（ P<0.05）。结论 为慢性心衰并低钠血症患者联用浓钠加托伐普坦可获得显著治疗效果， 同时对患者生存质量及预后也有积极影响。
【关键词】 托伐普坦 ;浓钠 ;慢性心力衰竭 ;低钠血症 ;效果 ;生存质量 ;预后 ;影响
Objective To observe the effect of atorvastatin on the prognosis of patients with chronic heart failure. Methods 80 patients with chronic heart failure and hyponatremia were divided into control group and study group, 40 cases in each group. Patients in the control group were treated with conventional treatment, while patients in the study group were treated with conventional treatment + concentrated sodium + tolvaptan. The treatment effect, mortality and quality of life scores before and after treatment were compared between the two groups. Results the clinical total effective rate of the study group was 95.00% higher than that of the control group (70.00%), and the mortality rate was 0 lower than 10.00% of the control group, the differences were statistically significant (P < 0.05). Before treatment, there was no significant difference in the scores of Minnesota Heart Failure Quality of life (mlhfq) between the two groups (P > 0.05); after treatment, the mlhfq scores of the two groups were lower than those before treatment, and the mlhfq score of the study group (30.13 ± 2.09) was lower than that of the control group (44.98 ± 5.56), the difference was statistically significant (P < 0.05). Conclusion for chronic heart failure patients with hyponatremia combined with concentrated sodium and tolvaptan can obtain significant therapeutic effect, at the same time, it has a positive impact on the quality of life and prognosis of patients.
出版日期
2020年09月14日（中国期刊网平台首次上网日期，不代表论文的发表时间）
